Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6EEV6
UPID:
SUMO4_HUMAN
Alternative names:
Small ubiquitin-like protein 4
Alternative UPACC:
Q6EEV6; A1L3W5
Background:
Small ubiquitin-related modifier 4 (SUMO4), a ubiquitin-like protein, plays a crucial role in post-translational modification. It attaches to target lysines on substrates, influencing their localization, stability, or activity. Notably, SUMO4's involvement extends to oxidative stress response, where it conjugates to anti-oxidant enzymes and stress defense proteins, modulating transcriptional activities of various genes including NFKBIA and NR3C1.
Therapeutic significance:
SUMO4's association with Type 1 diabetes mellitus 5 highlights its potential in disease modulation. Understanding the role of Small ubiquitin-related modifier 4 could open doors to potential therapeutic strategies, especially considering its impact on gene transcription and stress response mechanisms.